A5011044263- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Stress, Anesthesia, and Immune Response
- Long-Term Effects of COVID-19
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
- Histone Deacetylase Inhibitors Research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Glycosylation and Glycoproteins Research
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- T-cell and B-cell Immunology
Center of Molecular Immunology (Cuba)
2023-2024
There is an urgent need to understand severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-host interactions involved in virus spread and pathogenesis, which might contribute the identification of new therapeutic targets. In this study, we investigated presence SARS-CoV-2 postmortem lung, kidney, liver samples patients who died with disease (COVID-19) its relationship host factors using microscopy-based methods. The cases analyzed showed advanced stages diffuse alveolar damage...
Abstract Androgen deprivation therapy (ADT) is a standard for prostate cancer (PCa). Though disseminated disease initially sensitive to ADT, an important fraction of the patients progresses castration-resistant (CRPC). For this reason, identification novel effective therapies treating CRPC needed. Immunotherapeutic strategies focused on macrophages as antitumor effectors, directly enhancing their tumoricidal potential at tumor microenvironment or adoptive transfer after ex vivo activation,...
Interleukin-2 (IL-2) engineered versions, with biased immunological functions, have emerged from yeast display and rational design. Here we reshaped the human IL-2 interface receptor beta chain through screening of phage-displayed libraries. Multiple super-binders were obtained, having increased binding ability improved developability profiles. Selected variants exhibit an accumulation negatively charged residues at interface, which provides a better electrostatic complementarity to chain,...
Abstract Macrophages represent the most abundant immune component of tumor microenvironment and often exhibit protumorigenic (M2-like) phenotypes that contribute to disease progression. Despite their generally accepted role, macrophages can also display tumoricidal (or M1-like) behavior, revealing be functionally reprogrammed, depending on cues received within microenvironment. Moreover, such plasticity may achieved by pharmacologic or biologic interventions. To end, we previously...
Despite the cumulative evidence supporting HER3 as a target for antitumor therapies, no agents targeting have been approved cancer treatment. Most of evaluated in preclinical and clinical trials specific monoclonal antibodies (MAbs), with few examples active immunotherapy directed against this receptor. However, some vaccine formats may generate polyclonal (PAbs) that replicate diverse effector mechanisms MAbs, including ligand neutralization receptor degradation. In study, we developed...